Last reviewed · How we verify
Malignant neoplasm of breast
Approved treatments
- Avastin · Washington University School of Medicine
- Metholone · Eli Lilly
- Bevacizumab · Roche
Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR. - Avastin · Roche
Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Malignant neoplasm of breast patent landscape — cliff calendar, originator estates, attackable patents
- Malignant neoplasm of breast treatment landscape brief
- Malignant neoplasm of breast treatment updates RSS
Frequently asked questions about Malignant neoplasm of breast
What drugs treat Malignant neoplasm of breast?
Tracked treatments include Avastin, Metholone, Bevacizumab.
What is the treatment for Malignant neoplasm of breast?
Standard treatment for Malignant neoplasm of breast includes Avastin, Metholone, Bevacizumab. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Malignant neoplasm of breast patent cliff · Malignant neoplasm of breast CI report
- Treatment: Avastin · Washington University School of Medicine
- Treatment: Metholone · Eli Lilly
- Treatment: Bevacizumab · Roche
- Treatment: Avastin · Roche
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing